Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Neovasc Inc. (NVCN) Report Updated: Jun 16, 2018 | Print This Page

Get more stock ratings by Louis Navellier

Neovasc Inc. (NVCN)

Rating: Strong Sell Volatility: Aggressive
Total Grade: F Industry: Medical Specialties

Stock Analysis

Rating: Monthly View

June July August September October November December January February March April May

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

Neovasc Inc.© quotemedia

Company Profile

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; the Neovasc Reducer for the treatment of refractory angina; and a line of advanced biological tissue products called Peripatch that are used as components in third-party medical products comprising transcatheter heart valves. The company also provides a range of custom Peripatch products to industry customers for incorporation into their own products, such as transcatheter heart valves and other specialty cardiovascular devices; and consulting and original equipment manufacturing services to other medical device companies. In addition, it offers a line of collagen-based surgical patch products for use in cardiac reconstruction and vascular repair procedures, as well as other surgeries. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.